Eli Lilly and Company operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eli Lilly and Company with three other
companies in this sector in UNITED STATES :
sales of $34.61 billion
of which 34%
was Medical Devices),
Regeneron Pharmaceuticals Incorporated
of which 58%
was EYLEA), and
of which 71%
was Developed markets).
During the second
quarter of 2021, sales at Eli Lilly and Company totalled
an increase of 22.6%
from the $5.50 billion in sales at the company during the second quarter of 2020.
This was the biggest same quarter rise in sales at Eli Lilly and Company in the previous 35 quarters.
During the first two
quarters of 2021, sales totalled $13.55 billion, which is
than through the first two quarters of 2020.
There appears to be at least some degree of seasonality in the sales at Eli Lilly and Company: during 8 of the previous 9
years, sales were highest during the fourth quarter.
The exception to this was during 2013, when the
second quarter was the best quarter, accounting for
26% of sales (during that same year, the
fourth quarter accounted for 25% of sales).
Eli Lilly and Company reported sales of $24.54 billion
December of 2020.
increase of 9.9%
versus 2019, when the company's sales were $22.32 billion.
Despite this increase, sales are still
below the level achieved in 2018, when Eli Lilly and Company
reported sales of $24.56 billion.